Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































California Enacts First State Law to Combat Pay-for-Delay Rx Deals
/in Policy California Blogs, Featured News Home Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Sarah LanfordLast week, California enacted the first-in-the-nation state law to combat pay-for-delay deals between brand-name and generic pharmaceutical drug manufacturers. In a pay-for-delay deal, a brand manufacturer pays a generic competitor to settle patent litigation and keep the lower-cost version of the drug off the market. Delaying market entry of generic drugs limits competition and can […]
Legal Challenges to State Rx Laws
/in Policy Featured News Home, Toolkits Administrative Actions, Eligibility and Enrollment, Essential Health Benefits, Health Coverage and Access, Legal Resources, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffNavigating Legal Challenges to State Efforts to Control Drug Prices: PBM Regulation, Price Gouging, and Price Transparency Katherine L. Gudiksen, PhD, Samuel M. Chang, JD, and Jaime S. King, JD, PhD[1] In the last several years, states have increasingly attempted to use legislative efforts to control drug prices. Trade groups representing the interests of the […]
Nevada Fines Rx Manufacturers $17.4 Million for Failing to Explain Diabetes Medications’ Price Hikes
/in Policy Nevada Blogs, Featured News Home Cost, Payment, and Delivery Reform, Health System Costs, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer ReckLast week, Nevada fined 21 pharmaceutical companies $17.4 million for failing to submit a report explaining recent, significant price hikes to essential diabetes drugs, as required by the state’s drug cost transparency law. Faced with drug price increases far outpacing rates of inflation, states across the country are enacting transparency laws designed to shed light […]
Webinar for State Officials Only: Innovations in Medicaid Pharmacy Benefit Management Policies – A Look at Three States
/in Policy Ohio, Washington, West Virginia Webinars Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Prescription Drug Pricing, Quality and Measurement, State Rx Legislative Action, Value-Based Purchasing /by NASHP StaffLegal Landmines in Drug Pricing Laws: What’s a State To Do?
/in Policy Blogs Legal Resources, Prescription Drug Pricing, State Rx Legislative Action /by Trish RileyEvery state in the nation has proposed bills to limit pharmaceutical drug prices and the pace of that legislative work increases each year. The usual responses from pharmaceutical manufacturers and their allies is to threaten to reduce their investments in new drug research and development and challenge the new state laws in federal court. In […]
Implementing Rx Drug Transparency: States Are Shining a Light on High-Cost Drugs and their Impact on Premiums
/in Policy Maine, Oregon Blogs Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer ReckAs health plans prepare to submit rate filings, a new report from Oregon’s Division of Financial Regulation’s Prescription Drug Price Transparency Program illuminates just how much prescription drug prices impact insurance premiums. To increase health care cost transparency, Oregon requires health insurance companies to report on the impact of prescription drug prices on insurance plan […]
States on the Front Line: Addressing America’s Drug Pricing Problem
/in Policy Administrative Actions, Legal Resources, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Trish Riley and Sarah LanfordTo address America’s drug pricing problem, state policymakers face myriad conflicts and trade-offs, inadequate information about the “black box” of drug pricing, and an uncertain road map for how best to address the issue. This NASHP guest report, published in the September 2019 edition of the Journal of Legal Medicine, provides an overview of challenges states face […]
New PBM Laws Reflect States’ Targeted Approaches to Curb Prescription Drug Costs
/in Policy Blogs Cost, Payment, and Delivery Reform, Health System Costs, Medicaid Managed Care, Model Legislation, Prescription Drug Pricing, Quality and Measurement, State Rx Legislative Action /by Sarah Lanford and Maureen Hensley-QuinnIn 2019, states built on the momentum that had been gaining in recent years and passed targeted legislation to address the role harmful pharmacy benefit manager (PBM) business practices play in escalating prescription drug prices. The laws supporting these approaches, described below, give states enforcement mechanisms to ensure that the discounts that PBMs recoup are […]
Will Trump’s Drug Importation Plan Provide a Pathway for State Action?
/in Policy Blogs Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Trish RileyThe Trump Administration’s Safe Importation Action Plan lays out two pathways to support importation of lower-cost prescription drugs, but raises questions that need responses. In Pathway 1, the Administration gives a nod to state efforts to create wholesale importation programs for certain high-cost drugs, mirroring the provisions of current state efforts and federal requirements. That’s […]
In 2019, State Legislatures Took Targeted, Aggressive Steps to Curb Drug Spending
/in Policy Blogs, Featured News Home Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Sarah Lanford